OR WAIT null SECS
Via Nova Therapeutics’ VNT-101 is an Influenza A nucleoprotein inhibitor.
Via Nova Therapeutics announced that FDA has cleared its investigational new drug application for VNT-101.
The new therapy is a novel investigational small molecule that is described as an Influenza A nucleoprotein inhibitor. In a press release, Via Nova states that VNT-101 demonstrated activity in vitro against a variety of flu strains, including seasonal influenza A and avian influenza H5N1 and H7N9.
In the press release, Via Nova Therapeutics Ceo and co-founder Don Ganem, M.D., said, “We look forward to evaluating VNT-101 in the clinic. This is an important step to developing a flu antiviral with a novel mechanism of action, and a milestone for Via Nova Therapeutics as we advance our first compound into the clinic."
(Sept. 21, 2023); PR Newswire; Via Nova Therapeutics Announces FDA Clearance of Investigational New Drug Application for VNT-101, A Novel Direct-Acting Antiviral Against Influenza A Virus; https://www.prnewswire.com/news-releases/via-nova-therapeutics-announces-fda-clearance-of-investigational-new-drug-ind-application-for-vnt-101-a-novel-direct-acting-antiviral-against-influenza-a-virus-301934192.html?tc=eml_cleartime